<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Head and Neck Tumors</journal-id><journal-title-group><journal-title xml:lang="en">Head and Neck Tumors</journal-title><trans-title-group xml:lang="ru"><trans-title>Опухоли головы и шеи</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2222-1468</issn><issn publication-format="electronic">2411-4634</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">568</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>NEWS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>НОВОСТИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">New indications for the use of pembrolizumab in Russia: the use of the drug in the 1st line of treatment of recurrent and metastatic head and neck squamous cell carcinoma in single mode and in combination with chemotherapy has been approved</article-title><trans-title-group xml:lang="ru"><trans-title>Новые показания к применению пембролизумаба: в России одобрено применение препарата в 1-й линии терапии рецидивирующего и метастатического плоскоклеточного рака головы и шеи в монорежиме и в комбинации с химиотерапией</trans-title></trans-title-group></title-group><pub-date date-type="pub" iso-8601-date="2020-11-16" publication-format="electronic"><day>16</day><month>11</month><year>2020</year></pub-date><volume>10</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>118</fpage><lpage>119</lpage><history><date date-type="received" iso-8601-date="2020-11-16"><day>16</day><month>11</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2020-11-16"><day>16</day><month>11</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2020, Editorial A.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2020, Редакционная С.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="en">Editorial A.</copyright-holder><copyright-holder xml:lang="ru">Редакционная С.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://ogsh.abvpress.ru/jour/article/view/568">https://ogsh.abvpress.ru/jour/article/view/568</self-uri><abstract xml:lang="en"><p>.</p></abstract><trans-abstract xml:lang="ru"><p>.</p></trans-abstract><funding-group><funding-statement xml:lang="ru">Материал подготовлен при финансовой поддержке компании MSD RU-KEY-00650_10.20</funding-statement></funding-group></article-meta></front><body></body><back><ref-list/></back></article>
